ARTICLE | Clinical News
Faster-acting insulin aspart: Phase IIIa data
August 1, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase IIIa onset 1 trial in 1,143 Type I diabetics showed that subcutaneous FIAsp dosed at mealtime plus basal insulin met the primary endpoint of re...